Why RNA Biomarkers Are Poised to Transform Gastrointestinal Health (Geneoscopy | LinkedIn)

In a Q&A interview, Elizabeth Wurtzler, PhD, Director of R&D at Geneoscopy, explains how the company’s RNA-based stool test, ColoSense®, improves colorectal cancer screening by detecting active cancer-related signals less affected by age. She highlights recent modeling data showing ColoSense reduces CRC deaths more effectively than FIT, mt-sDNA, and blood-based tests at real-world adherence levels, while also proving cost-effective. Wurtzler also discusses a new scrape-free collection kit to boost screening compliance and outlines future RNA biomarker applications in inflammatory bowel disease (IBD).